The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Genomics in pharmaceuticals: embryonic stem cell culturing. Buy the report here.
According to GlobalData’s Technology Foresights, which uses over 691,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Embryonic stem cell culturing is a key innovation area in Genomics
Embryonic stem cells are cells derived from the human embryo and, owing to its pluripotent characteristics, they have a wide range of therapeutic applications. Embryonic culture helps in cultivating an embryo under aseptic conditions on a nutrient medium. Embryonic culture is of two types, namely mature and immature embryo culture.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 150+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of embryonic stem cell culturing.
Key players in embryonic stem cell culturing – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to embryonic stem cell culturing
|Company||Total patents (2010 - 2021)||Premium intelligence on the world's largest companies|
|Johnson & Johnson||758||Unlock company profile|
|Astellas Pharma||348||Unlock company profile|
|ViaCyte||314||Unlock company profile|
|Memorial Sloan Kettering Cancer Center||299||Unlock company profile|
|Lineage Cell Therapeutics||271||Unlock company profile|
|PT Soho Global Health||147||Unlock company profile|
|Sumitomo Chemical||124||Unlock company profile|
|Riken||112||Unlock company profile|
|Takara||89||Unlock company profile|
|Ministry of Trade and Industry, Singapore||76||Unlock company profile|
|Fujifilm||73||Unlock company profile|
|International Stem Cell||70||Unlock company profile|
|F. Hoffmann-La Roche||69||Unlock company profile|
|Platinum Equity||61||Unlock company profile|
|Geron||53||Unlock company profile|
|Takeda Pharmaceutical||41||Unlock company profile|
|Kadimastem||36||Unlock company profile|
|The Hospital for Sick Children||34||Unlock company profile|
|BioLamina||34||Unlock company profile|
|Cellatoz Therapeutics||31||Unlock company profile|
|Bristol-Myers Squibb||31||Unlock company profile|
|Imstem Biotechnology||30||Unlock company profile|
|The Cleveland Clinic Foundation||29||Unlock company profile|
|Children's Hospital & Medical Center||28||Unlock company profile|
|Procella Therapeutics||27||Unlock company profile|
|The New York Stem Cell Foundation||27||Unlock company profile|
|Daiichi Sankyo||23||Unlock company profile|
|Eisai||23||Unlock company profile|
|Vertex Pharmaceuticals||23||Unlock company profile|
|Cythera||20||Unlock company profile|
|Miltenyi Biotec||20||Unlock company profile|
|Centre National de la Recherche Scientifique||19||Unlock company profile|
|Fate Therapeutics||19||Unlock company profile|
|Organ Technologies||18||Unlock company profile|
|Massachusetts General Hospital||17||Unlock company profile|
|Pfizer||16||Unlock company profile|
|Children's Hospital of Philadelphia||16||Unlock company profile|
|Mclean Hospital||15||Unlock company profile|
|AgeX Therapeutics||15||Unlock company profile|
|Helmholtz Association of German Research Centres||13||Unlock company profile|
|Nexel||13||Unlock company profile|
|Children's Medical Center||13||Unlock company profile|
|Memphis Meats||12||Unlock company profile|
|S.Biomedics||11||Unlock company profile|
|General Hospital||11||Unlock company profile|
|Lifescan||10||Unlock company profile|
|Stem Cell & Regenerative Medicine International||10||Unlock company profile|
|Common Services Agency||10||Unlock company profile|
|UK Research and Innovation||10||Unlock company profile|
|MOH||9||Unlock company profile|
Source: GlobalData Patent Analytics
Johnson and Johnson is the leading patent filer in embryonic stem cell culturing. The company is involved in developing several regenerative medicines and human embryonic stem cells. It also entered several agreements with other companies for the development of embryonic stem cells. It has established the Committee on Advanced Therapies to ensure standards are maintained during cell culturing.
In terms of application diversity, Bristol-Myers Squibb is the top company, followed by Vertex Pharmaceuticals and Astellas Pharma. By means of geographic reach, Bristol-Myers Squibb also holds the top position, while Johnson & Johnson and Astellas Pharma are in the second and third positions, respectively.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Genomics.